Richard Busby Joins OncoBay leading Business Development

OncoBay Clinical - Richard Busby - LeadershipTAMPA, Fla. (July 07, 2020) — OncoBay Clinical, Inc., a full-service boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, is pleased to announce the expansion of their leadership team. OncoBay welcomes Richard Busby as Vice President of Marketing and Business Development.

“It’s exciting to join a team of clinical research professionals with such a great track record of success in the Oncology space with the support of the scientific leadership of Moffitt Cancer Center,” said Busby.

Busby brings over 25 years of experience in clinical research from both a clinical operations and business development background. He has a proven track record of success in companies such as PPD and Pharmalink FHI, which later became Novella Clinical. Busby began his career as a clinical research associate and project manager for a variety of phase I to IV clinical trials. He joined Novella Clinical in 2006, leading the functional outsourcing team before moving to a focus on oncology programs, supporting Novella’s Biotech and Pharma sponsors.

As a business development professional, Busby draws from his operational foundation, bringing practical experience and perspective to discussions with prospective clients. He has worked to assemble and offer a variety of creative models to meet his client’s needs – from functional service models to customized preferred providers of targeted services to full turn-key CRO solutions. Busby has experience in forging strategic relationships with emerging biotech customers, as well as assembling and serving on governance committees focused on key customer metrics and delivery of customized, proactive development solutions.

“The more time we spend upfront truly learning about a prospective sponsor’s clinical programs, understanding their operational challenges and learning their overall clinical and commercial goals, the better performance we can provide from day one. Given Richard’s strong background in both operations and business development, I have no doubt that he will lay the foundation in our client relationships to accomplish this.” said Krystyna Kowalczyk, president and CEO of OncoBay Clinical.

To learn more about OncoBay Clinical, please visit www.OncoBay.com.

About OncoBay Clinical

OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit OncoBay.com and follow us on Facebook, Twitter and LinkedIn.  

MEDIA CONTACT:

Deborah Turunjian

OncoBay Clinical, Vice-President Business Operations

970-535-0835

dturunjian@oncobay.comOncoBay Clinical - Richard Busby - Leadership

The Latest News & Events

SEE ALL NEWS & EVENTS

OncoBay Clinical Aims to Accelerate Immuno-Oncology Research

OncoBay Clinical Aims to Accelerate Immuno-Oncology Research

New immunotherapy-focused contract research organization offers end-to-end services for pharmaceutical and biotech companies

TAMPA, Fla. (June XX, 2020) — Oncology research has experienced an expansive transformation from the therapies tested and delivered less than a decade ago to those delivered today. In 2019, more than 400 immunotherapy products were available to patients and over 400 more were in development. These innovative therapies change the way we treat and manage patients. At OncoBay Clinical we know that new treatments with added complexities and unique safety profiles require a new approach, not just a band-aid on old methods. Innovation requires innovation. Introducing OncoBay Clinical, the next generation of contract research organization (CRO) support.

OncoBay Clinical, is a first-of-its-kind immuno-oncology CRO specializing in rare and complex oncology indications including immunotherapies and cellular therapies. A boutique CRO, OncoBay Clinical is a wholly owned for-profit subsidiary of Moffit Cancer Center. As a National Cancer Institute-designated Comprehensive Cancer Center, Moffitt has been at the forefront of development and research. Through direct partnership, OncoBay Clinical now leverages the unrivaled support of Moffitt’s top scientific advisors imbedding scientific expertise into every project team and creating “vein to vein” control of cell therapy (CTx) trials including those focused on tumor infiltrating lymphocyte (TIL) and chimeric antigen receptor T-cell (CAR T) therapies.

“OncoBay is filling a much-needed space in the industry, innovating in a way that is unprecedented. Our model revolutionizes the approach to oncology clinical trials and has been designed and built based upon the most difficult trials as a framework, thus allowing us to succeed in managing the most complex programs.” said Krystyna Kowalczyk, president and CEO of OncoBay Clinical. “Through our partnership with Moffitt Cancer Center, OncoBay Clinical has the ability to integrate scientific expertise with operational excellence and manufacturing capabilities to provide full service, custom curated solutions for our clients.”

OncoBay Clinical is a full-service CRO offering end-to-end services for pharmaceutical and biotech companies. Specializing in immuno-oncology clinical trials, OncoBay Clinical boasts a respected team of executive leaders with more than 100 years of oncology operations experience, all of whom are personally dedicated to the success of immuno-oncology clinical trials from start to finish.

To learn more about OncoBay Clinical, please visit www.OncoBay.com.

About OncoBay Clinical
OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit Oncobay.com and follow us on Facebook, Twitter and LinkedIn.

About Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.

 

MEDIA CONTACT:
Deborah Turunjian
OncoBay Clinical, Vice-President Business Operations
970-535-0835
dturunjian@oncobay.com

The Latest News & Events

SEE ALL NEWS & EVENTS

Webinar: Minimize Disruption of Your Oncology Trial in the era of COVID-19

Webinar: Minimize Disruption of Your Oncology Trial in the era of COVID-19

XTALKS WEBINAR ABSTRACT & DETAILS

Date: Tuesday, June 23, 2020
Time: 12:00-1:00 PM EST
Webinar Title: Minimize Disruption of Your Oncology Trial in the era of COVID-19

Oncology trials always come with their share of complexities and challenges. Since its onset, COVID-19 has had the industry’s undivided attention, with clinical trial professionals adapting clinical trial operational plans to accommodate. From data integrity to participant recruitment and retention, our industry has temporarily reconsidered long held habits. As the world begins to relax restrictions, what are the lessons learned that can catapult us into the next innovation in trial operations for good?

In this webinar, our panel of experts share examples and lessons learned during the COVID-19 window and explore how those lessons can drive meaningful change over the next 12 months including:

• Leveraging technology to maximize risk and quality oversight
• Maximizing the patient experience and patient retention
• Designing trials to collect the data we need
• Managing missing data and redesigning analyses to account for anomalies like COVID


Who should attend?

• Clinical affairs professionals
• Medical affairs professionals
• R&D Heads
• Oncology clinical professionals
• Oncology-focused biotech and pharmaceutical companies
• Clinical trial coordinators and Site Managers

Speakers:
• Moffitt: Cristina Naso
• OncoBay: Dannelle Palmer, VP Clinical Operations
• Veristat, Biometrics
• Veristat, Regulatory

REGISTER FOR WEBINAR

The Latest News & Events

SEE ALL NEWS & EVENTS

Moffitt Cancer Center Launches Immunotherapy Contract Research Organization

Moffitt Cancer Center Launches Immunotherapy Contract Research Organization

The new organization will provide end-to-end services for pharmaceutical and biotech companies seeking to accelerate immuno-oncology and cell therapy research.

NEWS PROVIDED BY
Moffitt Cancer Center
Oct 03, 2019, 10:01 ET

TAMPA, Fla., Oct. 3, 2019 /PRNewswire/ — Moffitt Cancer Center announced today the launch of a first-of-its-kind contract research organization (CRO) focused on accelerating immunotherapy research. The subsidiary will provide a one-stop-shop for pharmaceutical and biotech companies to accelerate their immuno-oncology and cell therapy research through collaborative clinical trial support and administration.

Read More

The Latest News & Events

SEE ALL NEWS & EVENTS

Krystyna Kowalczyk Named CEO of Moffitt Cancer Center’s Immunotherapy Contract Research Organization

Krystyna Kowalczyk Named CEO of Moffitt Cancer Center’s Immunotherapy Contract Research Organization
TAMPA, Fla. — Krystyna Kowalczyk has joined Moffitt Cancer Center as the chief executive officer of the institution’s new contract research organization (CRO) with a focus on immunotherapy. The wholly owned, for profit subsidiary, first announced in October 2019, will offer end-to-end services for pharmaceutical and biotech companies looking to advance their immuno-oncology product or device.

Read more

The Latest News & Events

SEE ALL NEWS & EVENTS

People On the Move: Krystyna Kowalczyk; CEO of Moffitt’s Contract Research Organization

People On the Move: Krystyna Kowalczyk; CEO of Moffitt’s Contract Research Organization
February 26, 2020:  CEO of Moffitt’s Contract Research Organization at H. Lee Moffitt Cancer Center & Research Institute

To read more about the press release. 

The Latest News & Events

SEE ALL NEWS & EVENTS

Take Advantage of OncoBay’s Innovative Approach

CONTACT ONCOBAY CLINICAL

Submit a Request for Proposal

Submit Proposal

OncoBay is now Kapadi

 

Once three entities – OncoBay Clinical, Clinscience, and Exom Group s.r.l – now we stand as one, bringing forth a symphony of expertise and seamless operations. To celebrate our unity, we re-brand under the banner of Kapadi, and embark on a new chapter of exceptional service in oncology clinical research.

Kapadi is not just a name; it's a testament to our fusion. It signifies the our standing as a global CRO powerhouse committed to accelerating groundbreaking cancer therapies that uplift patients worldwide. From conceptualizing studies, navigating regulations, and analyzing data, we provide a comprehensive array of services designed to empower your oncology clinical trials.

 

Visit Kapadi.com

 

This window will auto-close in 15 seconds.

This will close in 7 seconds